Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Tuesday, down -0.29% from the previous trading day, before settling in for the closing price of $13.99. Over the past 52 weeks, DNLI has traded in a range of $10.57-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -4.46% over the last five years. While this was happening, its average annual earnings per share was recorded -18.32%. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
The firm has a total of 422 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.15%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -18.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.56% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.74 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 2.02 million was better than the volume posted last year of 1.37 million. As of the previous 9 days, the stock’s Stochastic %D was 41.86%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 25.58%, which indicates a significant increase from 23.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.76% in the past 14 days, which was lower than the 69.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.46, while its 200-day Moving Average is $20.32. Now, the first resistance to watch is $14.46. This is followed by the second major resistance level at $14.98. The third major resistance level sits at $15.29. If the price goes on to break the first support level at $13.63, it is likely to go to the next support level at $13.32. Should the price break the second support level, the third support level stands at $12.80.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 2.03 billion has total of 145,276K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -422,770 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -132,970 K.
